A b s t r a c t
Serum testing for levels of κ and λ free light chains (FLCs) represents an important diagnostic tool when evaluating for the presence of monoclonal plasma cell disorders (PCDs). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Current pathology guidelines for the evaluation of suspected monoclonal gammopathies recommend 24-hour urine samples for urine protein electrophoresis (UPEP), in addition to serum protein electrophoresis (SPEP). 13 However; these recommendations were published in 1999, before the availability of serum FLC (sFLC) testing.
When evaluating for monoclonal gammopathies, recent studies support the use of a serum panel that combines the sFLCs with SPEP and/or serum immunofixation (IFE) 1, 7, 9 and the elimination of urine studies from the screening algorithm. 7, 9 The physiologic rationale for eliminating urine studies is that if FLCs are present and measurable in the serum, testing the urine for analogous proteins only confirms that FLCs were filtered through the glomerulus and exceeded the reabsorption threshold in the proximal convoluted tubules. Moreover, UPEP is limited by analytic problems and imprecision in clinically relevant ranges. 14 In addition, a serum panel eliminates the burden of a 24-hour urine collection for which compliance is often low. One laboratory group reported that concomitant urine specimens were received sporadically (only 40% of the time), and, therefore, the serum panel would eliminate the need for 24-hour urine collection. 2 At Walter Reed Army Medical Center, Washington, DC, concomitant serum and urine specimens are received approximately 35% of the time.
However, several studies have reported limitations to the use of the serum panel. Beetham et al 15 supported urine testing despite little difference in outcomes between urine Bence Jones protein analysis and sFLC testing. Moreover, Hill et al 7 reported false-positive sFLC results in the setting of renal insufficiency and/or hypergammaglobulinemia as another limitation when using sFLC testing. However, the frequency of false-positive results in patients with renal impairment was not reported, and no quantitative estimate of renal insufficiency was provided in their study.
Before a consensus can be reached to support eliminating UPEP from the assessment for PCD, sFLC testing requires further assessment with respect to reference intervals as they relate to renal impairment and polyclonal hypergammaglobulinemia. It is important to note that reference intervals for free κ, free λ, and the κ/λ ratio were assigned by studying serum samples of healthy subjects. 8 Thus, the impact of clinically important renal impairment on sFLC results was not known or appreciated when reference intervals were initially defined. In healthy people, κ FLC production is at least twice that of λ (ratio ≥2.0), but a more rapid renal clearance of κ vs λ FLCs leads to a median κ/λ ratio of approximately 0.6. 8 In the setting of renal insufficiency and/or polyclonal hypergammaglobulinemia, serum κ and λ concentrations increase. 7, 8 If these processes overwhelm renal clearance mechanisms, a κ/λ ratio of 2.0 or slightly higher may be consistent with physiologic limits.
In this study, sFLC testing was performed in combination with SPEP and UPEP to determine the value of the serum panel vs the panel of SPEP/UPEP. The results of sFLC testing were evaluated relative to serum creatinine concentrations and the presence of polyclonal hypergammaglobulinemia to determine the impact of these comorbidities on sFLC results.
Materials and Methods
This study was conducted in the Department of Pathology Core Laboratory at Walter Reed Army Medical Center. The protocol was approved by the governing institutional review board. During a 3-month period in 2007, residual serum samples were collected and frozen at -20°C from patients who had concomitant (within 2 weeks) SPEP, UPEP (random or 24-hour), and serum creatinine testing ordered for routine clinical purposes. The serum samples were stored until thawed and subsequently assayed for sFLCs. All eligible samples were accrued without regard to the indication for testing or the underlying diagnoses, which were unknown to the investigators throughout the study. Samples were excluded if insufficient residual serum remained for sFLC testing or if more than 1 sample was received from individual patients. A PCD was considered unequivocally present if the SPEP and/ or the UPEP showed a monoclonal band; "faint" bands on UPEP were not considered unequivocal PCD.
Routine testing for SPEP and UPEP was performed using agarose gels that were stained with acid blue stain on the REP1 system (Helena Laboratories, Beaumont, TX). Urine samples were concentrated to a maximum of 100×. All gels and densitometric scans were interpreted as per routine specimen processing before and independent of FLC assessment. Samples with a monoclonal abnormality identified by protein electrophoresis were "reflexed" to testing with IFE using antisera to IgA, IgM, IgG, κ, and λ on SPIFE IFE 9/15 gels (Helena Laboratories). Serum creatinine levels were determined using dry slide technology via the amidohydrolase method on an Ortho 5,1 FS analytic platform (Ortho Clinical Diagnostics, Rochester, NY).
Automated immunoturbidimetric assays for free κ and free λ were performed on a Bayer Advia 1650 (Bayer Diagnostics, Tarrytown, NY) using commercial reagents (Freelite, The Binding Site, Birmingham, England). The κ/λ ratio was calculated. Results of sFLC testing were considered abnormal if the κ/λ ratio was abnormal and at least 1 FLC concentration was more than the reference interval in accordance with prior clinical reports. 10, 16 The results for sFLC testing performed as part of this study were not divulged to the ordering physician. For samples with isolated sFLC or urine abnormalities, laboratory records were searched for results of follow-up electrophoretic testing during the following 6 months.
Results
The 281 unique patient samples were from 118 women (median age, 64 years; range, 22-94 years) and 163 men (median age, 69 years; range, 21-98 years). A flow chart depicting the results of SPEP, UPEP, and sFLC is shown in zFigure 1z, and a summary of laboratory findings is given in zTable 1z.
Polyclonal Hypergammaglobulinemia
There were 16 patients with no monoclonal bands on SPEP or UPEP, normal serum creatinine levels, and polyclonal hypergammaglobulinemia (median γ fraction, 1.76 g/ dL [18 g/L]; range, 1.53-4.06 g/dL [15-41 g/L]). The median κ was 19 mg/L (range, 0.75-108.7 mg/L), the median λ was 18.45 mg/L (range, 0.86-53.6 mg/L), and the median κ/λ ratio was 1.06 (range, 0.71-2.11). Only 1 of the patients had an increased κ/λ ratio zTable 2z (row 13).
One patient had polyclonal hypergammaglobulinemia and an increased serum creatinine level and no monoclonal band on SPEP or UPEP but had a decreased κ/λ ratio (0.14), and was diagnosed with PCD (see "Plasma Cell Disorders").
Renal Insufficiency
There were 48 patients with increased serum creatinine levels and normal SPEP, UPEP, and κ/λ ratio results. It is important to note that mildly increased κ-biased ratios between 1.65 and 3.1 with an increased light chain concentration were observed in 10 patients with renal insufficiency but no M spikes were seen on SPEP or UPEP (Table 2 , rows 3-12). Six (60%) of these 10 patients with mildly increased ratios and renal impairment also had polyclonal hypergammaglobulinemia. In contrast, among the 48 other patients with renal insufficiency who had no discrete bands on SPEP or UPEP and normal sFLC results, only 5 (10%) had polyclonal hypergammaglobulinemia. There were 33 patients with PCD who also had renal impairment. The cases are discussed in the next section.
Plasma Cell Disorders
A monoclonal band was identified by SPEP in 74 patient samples. A monoclonal band was also identified by UPEP in 26 of these 74 samples. Three additional urine samples showed faint bands that were unassociated with FLCs; however, concomitant SPEP and sFLC results were negative, and 2 of the 3 patients had polyclonal patterns on SPEP. For these 3 patients, the clinical laboratory did not receive follow-up serum or urine samples. Thus, the clinical outcome and final diagnoses of these 3 patients were unknown, and they were considered equivocal for this analysis zTable 3z (rows 3-5).
Two samples demonstrated clonal bands by UPEP and concomitant sFLC abnormalities; however, both were negative by SPEP (Table 3, rows 1-2) . The results of sFLC demonstrated abnormalities in 32 of the 74 samples with an abnormal SPEP result and 2 with a positive UPEP result. Of these 34 samples, 20 had κ and 14 had λ abnormalities. Of the 20 samples with free κ light chain abnormalities and concomitant monoclonal bands shown on SPEP, 6 had a κ/λ ratio between 1.65 and 3.1 zTable 4z. Among the 16 patients with κ monoclonal processes identified by sFLC results (14 with abnormal SPEP and 2 with abnormal UPEP results), the minimum κ/λ ratio was 3.5, the median ratio was 17.9, and the median free κ concentration was 196 mg/L.
Among the 14 patients with λ bands present on SPEP and sFLC abnormalities, the median free λ concentration was 160 mg/L, and the median κ/λ ratio was 0.12. Results from 1 patient with a serum free λ concentration of 125.4 mg/L, a free κ of 43.0 mg/L, and a serum creatinine concentration of 1.8 mg/L (159 µmol/L) were interpreted as consistent with PCD, despite a borderline normal ratio of 0.34. In the setting of renal insufficiency, the uninvolved free κ increased, albeit mildly, and the interpretation of sFLC results was consistent with a λ PCD. SPEP and serum IFE demonstrated an IgG λ clone in this patient. Fifteen samples demonstrated sFLC abnormalities but were negative with SPEP and UPEP ( Table 2 ). In 2 of 15 samples, the ratios were λ biased, and follow-up electrophoretic studies for these patients were consistent with a λ monoclonal gammopathy ( Table 2, rows 1-2) .
Overall, there were 34 abnormalities with sFLC results (28 concordant with SPEP, 2 concordant with UPEP, 2 new gammopathies, and 2 equivocal). With UPEP, there were 31 abnormalities (26 concordant with SPEP, 2 concordant with sFLC testing, and 3 equivocal). By using the serum panel of SPEP and sFLCs, 2 additional monoclonal processes were detected, with fewer equivocal results when the higher cutoff of 3.1 was used for renal impairment and polyclonal processes compared with SPEP and UPEP zFigure 2z.
Discussion
For many years, SPEP and UPEP have been the backbone of laboratory screening for monoclonal gammopathies. However, the introduction of sFLC testing provides a new diagnostic tool that has fostered change in the diagnostic approach to PCD assessment. Our findings support use of a serum panel of SPEP/sFLC when screening for PCD, as has been previously reported. 1, 7 To improve specificity of sFLC testing, our findings support extending the reference interval for the κ/λ ratio to 3.1 for patients with renal insufficiency and/or polyclonal hypergammaglobulinemia. It is important to note that in most of these patients the levels of both free κ and free λ were above normal, reflecting slowed renal light chain clearance rather than a rare biclonal oligosecretory gammopathy. A second study may be required to strengthen the implications of our observations and to establish appropriate reference intervals in these settings. Compared with the serum creatinine level, estimated glomerular filtration rate and creatinine clearance provide a more accurate assessment of renal function, but these tests are not performed as frequently as serum creatinine levels in most laboratories. Therefore, the serum creatinine level was used as a surrogate of renal function in this study, and most clinicians would be able to quickly interpret sFLC testing relative to serum creatinine levels. Similarly, in most laboratories, clinical diagnoses and the treatment status of most patients are unknown when samples are analyzed; therefore, our protocol recapitulated the typical challenges that are routinely confronted in the laboratory. Finally, in many clinical laboratories, SPEP represents a first step in the diagnostic algorithm for PCD. If there is a monoclonal band, asymmetry in a polyclonal pattern, or a suspicion of PCD, serum IFE is performed as per current guidelines. 13 Thus, our protocol followed most routine laboratory procedures.
In renal insufficiency, κ light chains typically predominate. Thus, an excess of light chains is highly suggestive of a λ PCD. In one of our patients with an increased serum creatinine concentration, there was a markedly increased λ concentration despite a normal κ/λ ratio. Therefore, the interpretation was consistent with a PCD. This clinical manifestation was reported previously in a patient at Boston University with λ light chain deposition disease in which the free λ was 75.0 mg/L, free κ was 18.8 mg/L, and the κ/λ ratio was normal at 0.28. After treatment, these values were 21.7, 10.1, and 0.47, respectively. 17 In our study, fewer than half of the patients with monoclonal bands shown on SPEP had concordant abnormalities by UPEP or sFLC testing. Monoclonal gammopathy of undetermined significance (MGUS) is the most common monoclonal gammopathy. However, only one third of patients with MGUS have an abnormal sFLC ratio at baseline, and these patients are at higher risk of experiencing progression to other PCDs. 18 This phenomenon could explain the disparity between the number of gammopathies that were identified on SPEP vs sFLC testing in our study.
Since the introduction of the sFLC assays, the usefulness of UPEP assessment may be less evident in the evaluation of PCDs. The focus of recently published studies is the replacement of urine testing with sFLC testing. 7, 15 A study from the United Kingdom found that a strategy of using sFLCs instead of UPEP would have missed 1 paraprotein (MGUS) in 923 patients, and, therefore, the authors supported use of the serum panel and elimination of UPEP. 7 Another group of investigators from the Mayo Clinic concluded that a serum panel of IFE and sFLC testing could replace urine testing. 9 Only one UK study concluded that it was not yet time to eliminate UPEP, although the authors conceded that little difference in outcome would have been observed between the serum panel and SPEP/UPEP in that just "one patient with Bence Jones protein MGUS would have been missed." 15 Our study demonstrates that perhaps through a better understanding and use of panels with SPEP and sFLC testing, UPEP assessment may soon become an inferior tool in the assessment for PCD. If larger scale studies continue to strengthen and support this important observation, perhaps a global consensus will identify UPEP testing as an exercise and discussion for historical text books and teaching points. And perhaps such literature might compare the usefulness of UPEP testing in the evaluation of PCD with that of myoglobin or lactate dehydrogenase testing in the assessment of myocardial infarction. 
